Go Pro
→ Buy this stock tomorrow (From Chaikin Analytics) (Ad)tc pixel Free FHTX Stock Alerts

Foghorn Therapeutics (FHTX) Financials

Foghorn Therapeutics logo
$5.30 +0.29 (+5.79%)
Closing price 04:00 PM Eastern
Extended Trading
$5.31 +0.01 (+0.25%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Foghorn Therapeutics

Annual Income Statements for Foghorn Therapeutics

This table shows Foghorn Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -51 -69 -101 -109 -98 -87 -74
Consolidated Net Income / (Loss)		 -51 -69 -101 -109 -98 -87 -74
Net Income / (Loss) Continuing Operations		 -51 -69 -101 -109 -98 -87 -74
Total Pre-Tax Income 		-51 -69 -101 -109 -94 -87 -74
Total Operating Income		 -51 -69 -101 -117 -108 -103 -86
Total Gross Profit		 0.00 0.43 1.32 19 34 23 31
Total Revenue		 0.00 0.43 1.32 19 34 23 31
Operating Revenue		 0.00 0.43 1.32 19 34 23 31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 51 69 102 136 142 125 117
Selling, General & Admin Expense		 6.72 11 22 31 32 28 28
Research & Development Expense		 44 58 80 106 110 95 85
Other Operating Expenses / (Income)		 - - - - - - -1.63
Impairment Charge		 - - - - 0.00 2.40 5.91
Total Other Income / (Expense), net		 -0.04 -0.27 -0.59 8.26 14 16 12
Interest & Investment Income		 - - 0.06 5.68 11 12 8.75
Other Income / (Expense), net		 0.50 0.93 2.49 2.58 2.83 4.16 3.36
Basic Earnings per Share		 ($12.20) ($6.23) ($2.73) ($2.62) ($2.34) ($1.58) ($1.18)
Weighted Average Basic Shares Outstanding		 4.19M 11.05M 37.17M 41.59M 41.97M 54.90M 62.98M
Diluted Earnings per Share		 ($12.20) ($6.23) ($2.73) ($2.62) ($2.34) ($1.58) ($1.18)
Weighted Average Diluted Shares Outstanding		 4.19M 11.05M 37.17M 41.59M 41.97M 54.90M 62.98M
Weighted Average Basic & Diluted Shares Outstanding		 4.19M 11.05M 41.42M 41.80M 42.57M 55.61M 58.70M

Quarterly Income Statements for Foghorn Therapeutics

This table shows Foghorn Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -25 -25 -23 -19 -20 -19 -18 -16 -22 -20
Consolidated Net Income / (Loss)		 -14 -24 -25 -23 -19 -20 -19 -18 -16 -22 -20
Net Income / (Loss) Continuing Operations		 -14 -24 -25 -23 -19 -20 -19 -18 -16 -22 -20
Total Pre-Tax Income 		-14 -22 -25 -23 -19 -20 -19 -18 -16 -22 -20
Total Operating Income		 -17 -25 -28 -27 -24 -24 -23 -21 -19 -24 -22
Total Gross Profit		 17 5.77 5.05 6.89 7.81 2.86 5.95 7.56 8.15 9.25 3.27
Total Revenue		 17 5.77 5.05 6.89 7.81 2.86 5.95 7.56 8.15 9.25 3.27
Operating Revenue		 17 5.77 5.05 6.89 7.81 2.86 5.95 7.56 8.15 9.25 3.27
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 35 31 33 34 32 27 29 29 27 33 25
Selling, General & Admin Expense		 8.31 7.02 7.71 7.33 6.97 6.35 7.24 6.86 6.65 6.80 6.58
Research & Development Expense		 26 24 26 24 25 21 22 22 20 22 18
Total Other Income / (Expense), net		 3.47 3.34 3.18 3.65 4.73 4.50 4.08 3.16 2.65 2.21 1.70
Interest & Investment Income		 2.75 2.66 2.44 2.87 3.50 3.10 2.69 2.31 2.03 1.71 1.74
Other Income / (Expense), net		 0.72 0.68 0.74 0.78 1.24 1.41 1.39 0.85 0.62 0.50 -0.04
Basic Earnings per Share		 ($0.34) ($0.57) ($0.59) ($0.45) ($0.31) ($0.23) ($0.30) ($0.28) ($0.25) ($0.35) ($0.29)
Weighted Average Basic Shares Outstanding		 42.03M 41.97M 42.43M 51.58M 62.60M 54.90M 62.85M 62.98M 63.03M 62.98M 69.54M
Diluted Earnings per Share		 ($0.34) ($0.57) ($0.59) ($0.45) ($0.31) ($0.23) ($0.30) ($0.28) ($0.25) ($0.35) ($0.29)
Weighted Average Diluted Shares Outstanding		 42.03M 41.97M 42.43M 51.58M 62.60M 54.90M 62.85M 62.98M 63.03M 62.98M 69.54M
Weighted Average Basic & Diluted Shares Outstanding		 42.22M 42.57M 42.59M 55.33M 55.59M 55.61M 55.74M 56.53M 56.55M 58.70M 58.71M

Annual Cash Flow Statements for Foghorn Therapeutics

This table details how cash moves in and out of Foghorn Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -23 77 8.34 -49 28 -25 27
Net Cash From Operating Activities		 -46 -31 -50 194 -118 -100 -86
Net Cash From Continuing Operating Activities		 -46 -31 -50 194 -118 -100 -86
Net Income / (Loss) Continuing Operations		 -51 -69 -101 -109 -98 -87 -74
Consolidated Net Income / (Loss)		 -51 -69 -101 -109 -98 -87 -74
Depreciation Expense		 0.69 1.33 3.23 3.32 3.45 3.12 3.33
Amortization Expense		 0.00 -0.00 0.18 -1.30 -2.65 -4.61 -1.93
Non-Cash Adjustments To Reconcile Net Income		 2.90 7.49 -286 319 21 20 12
Changes in Operating Assets and Liabilities, net		 1.20 29 333 -18 -42 -32 -25
Net Cash From Investing Activities		 -0.96 -109 36 -244 144 -30 112
Net Cash From Continuing Investing Activities		 -0.96 -109 36 -244 144 -30 112
Purchase of Property, Plant & Equipment		 -0.97 -16 -3.31 -1.21 -1.22 -0.91 -0.05
Purchase of Investments		 0.00 -93 -100 -409 -74 -261 -131
Sale and/or Maturity of Investments		 - 0.00 139 166 220 232 243
Net Cash From Financing Activities		 24 217 22 1.76 1.78 105 1.02
Net Cash From Continuing Financing Activities		 24 217 22 1.76 1.78 105 1.02
Repurchase of Common Equity		 - - - - 0.00 -0.59 0.00
Issuance of Common Equity		 0.00 122 42 - 0.00 103 0.54
Other Financing Activities, net		 0.69 1.22 1.42 1.76 1.78 2.61 0.48
Cash Income Taxes Paid		 - - - - 3.55 0.86 0.01

Quarterly Cash Flow Statements for Foghorn Therapeutics

This table details how cash moves in and out of Foghorn Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 13 10 -1.08 60 -81 -2.22 5.57 13 17 -8.46 6.79
Net Cash From Operating Activities		 -27 -28 -29 -26 -21 -25 -24 -21 -19 -22 -25
Net Cash From Continuing Operating Activities		 -27 -28 -29 -26 -21 -25 -24 -21 -19 -22 -25
Net Income / (Loss) Continuing Operations		 -14 -24 -25 -23 -19 -20 -19 -18 -16 -22 -20
Consolidated Net Income / (Loss)		 -14 -24 -25 -23 -19 -20 -19 -18 -16 -22 -20
Depreciation Expense		 0.86 0.85 0.84 0.79 0.73 0.76 0.83 0.85 0.85 0.80 0.24
Amortization Expense		 -0.66 -0.50 -0.55 -0.71 -1.79 -1.57 -0.82 -0.45 -0.36 -0.31 -0.39
Non-Cash Adjustments To Reconcile Net Income		 5.42 4.45 4.64 7.02 4.40 3.91 4.14 4.25 3.43 0.35 2.94
Changes in Operating Assets and Liabilities, net		 -18 -8.24 -9.25 -9.66 -5.23 -8.12 -9.28 -7.72 -6.94 -1.46 -8.19
Net Cash From Investing Activities		 38 37 27 -18 -61 22 29 34 36 13 -18
Net Cash From Continuing Investing Activities		 38 37 27 -18 -61 22 29 34 36 13 -18
Purchase of Property, Plant & Equipment		 -0.08 -0.04 -0.10 -0.02 -0.31 -0.48 -0.03 -0.02 - - 0.00
Purchase of Investments		 -3.86 -6.84 -31 -66 -124 -40 -51 -42 -4.00 -34 -67
Sale and/or Maturity of Investments		 42 44 58 48 63 62 81 76 40 47 49
Net Cash From Financing Activities		 1.39 0.19 1.17 103 1.05 0.00 0.14 0.25 0.05 0.58 50
Net Cash From Continuing Financing Activities		 1.39 0.19 1.17 103 1.05 0.00 0.14 0.25 0.05 0.58 50
Repurchase of Common Equity		 - - - - -0.39 - 0.00 - - - -0.32
Issuance of Common Equity		 - - - - - - 0.00 - - 0.54 50
Other Financing Activities, net		 1.39 0.19 1.17 - 1.44 0.00 0.14 0.25 0.05 0.04 0.09
Cash Income Taxes Paid		 1.00 0.87 0.05 0.71 0.06 0.05 0.00 0.00 - 0.00 0.00

Annual Balance Sheets for Foghorn Therapeutics

This table presents Foghorn Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 256 520 405 286 284 198
Total Current Assets		 17 191 460 351 240 250 163
Cash & Equivalents		 15 93 101 52 80 55 81
Restricted Cash		 0.54 - - - - 0.00 1.25
Short-Term Investments		 0.00 93 53 294 154 188 78
Prepaid Expenses		 1.36 4.92 5.27 5.60 6.12 5.85 3.09
Plant, Property, & Equipment, net		 2.68 20 18 15 13 9.96 1.92
Total Noncurrent Assets		 2.77 45 43 38 33 24 33
Other Noncurrent Operating Assets		 2.77 45 43 38 33 24 33
Total Liabilities & Shareholders' Equity		 22 256 520 405 286 284 198
Total Liabilities		 24 109 423 405 363 330 307
Total Current Liabilities		 13 19 49 55 58 67 60
Accounts Payable		 3.44 13 13 16 15 12 16
Current Deferred Revenue		 0.00 2.02 28 33 35 46 43
Other Current Liabilities		 1.36 3.98 6.99 5.97 8.52 9.07 0.92
Total Noncurrent Liabilities		 11 91 374 350 305 263 247
Noncurrent Deferred Revenue		 0.00 13 323 304 268 234 206
Other Noncurrent Operating Liabilities		 0.20 58 51 46 37 28 41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -88 146 97 0.11 -77 -46 -109
Total Preferred & Common Equity		 -88 146 97 0.11 -77 -46 -109
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -88 146 97 0.11 -77 -46 -109
Common Stock		 6.12 309 361 377 395 513 524
Retained Earnings		 -94 -163 -264 -373 -472 -558 -632
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.01 -3.99 -0.83 0.14 0.02

Quarterly Balance Sheets for Foghorn Therapeutics

This table presents Foghorn Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 313 255 329 308 259 226 205 222
Total Current Assets		 265 212 290 271 225 204 184 188
Cash & Equivalents		 70 79 139 58 61 73 89 88
Restricted Cash		 - - - - - 1.25 1.25 1.25
Short-Term Investments		 190 127 146 210 160 126 91 96
Prepaid Expenses		 5.55 4.86 4.44 3.84 4.83 3.93 2.59 3.18
Plant, Property, & Equipment, net		 14 12 11 11 10 9.51 8.66 1.71
Total Noncurrent Assets		 34 31 28 27 23 13 12 32
Other Noncurrent Operating Assets		 34 31 28 27 23 13 12 32
Total Liabilities & Shareholders' Equity		 313 255 329 308 259 226 205 222
Total Liabilities		 371 352 343 337 320 303 295 299
Total Current Liabilities		 52 52 51 57 71 78 85 64
Accounts Payable		 15 12 11 15 11 12 13 10
Current Deferred Revenue		 28 32 31 33 52 60 65 52
Other Current Liabilities		 8.37 8.67 8.38 8.77 9.11 6.18 6.76 1.86
Total Noncurrent Liabilities		 319 300 292 280 249 225 210 234
Noncurrent Deferred Revenue		 280 266 259 250 222 207 193 194
Other Noncurrent Operating Liabilities		 39 34 33 30 27 18 16 41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -57 -97 -14 -28 -62 -77 -90 -76
Total Preferred & Common Equity		 -57 -97 -14 -28 -62 -77 -90 -76
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -57 -97 -14 -28 -62 -77 -90 -76
Common Stock		 392 400 506 510 515 518 521 576
Retained Earnings		 -447 -497 -520 -539 -577 -595 -611 -652
Accumulated Other Comprehensive Income / (Loss)		 -1.89 -0.50 -0.34 0.36 0.01 -0.04 0.02 -0.13

Annual Metrics And Ratios for Foghorn Therapeutics

This table displays calculated financial ratios and metrics derived from Foghorn Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 35,813,580.00 37,091,588.00 41,801,928.00 42,217,126.00 - 56,551,289.00
DEI Adjusted Shares Outstanding		 0.00 35,813,580.00 37,091,588.00 41,801,928.00 42,217,126.00 - 56,551,289.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.92 -2.73 -2.60 -2.33 - -1.31
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 206.74% 1,357.77% 77.63% -33.83% 36.75%
EBITDA Growth		 0.00% -32.82% -43.10% -18.66% 7.34% 4.09% 18.39%
EBIT Growth		 0.00% -33.63% -45.33% -16.61% 8.28% 6.24% 15.72%
NOPAT Growth		 0.00% -34.15% -46.99% -16.28% 7.88% 4.84% 15.87%
Net Income Growth		 0.00% -34.56% -47.27% -7.46% 9.60% 11.99% 14.24%
EPS Growth		 0.00% 48.93% 56.18% 4.03% 10.69% 32.48% 25.32%
Operating Cash Flow Growth		 0.00% 32.48% -60.62% 485.30% -161.00% 14.99% 14.25%
Free Cash Flow Firm Growth		 0.00% 0.00% -10.36% 724.60% -153.31% 14.66% 13.58%
Invested Capital Growth		 0.00% -958.93% -188.11% -502.05% 9.96% 7.06% 7.13%
Revenue Q/Q Growth		 0.00% 0.00% 53.91% 22.03% 4.87% -11.42% 26.07%
EBITDA Q/Q Growth		 0.00% 0.00% -7.95% -4.02% 5.92% 1.01% 0.64%
EBIT Q/Q Growth		 0.00% 0.00% -8.06% -3.36% 5.81% 2.17% -0.94%
NOPAT Q/Q Growth		 0.00% 0.00% -7.82% -3.36% 5.62% 1.40% 0.15%
Net Income Q/Q Growth		 0.00% 0.00% -9.02% 0.24% 4.63% 5.05% -3.00%
EPS Q/Q Growth		 0.00% 0.00% -605.56% 2.96% 4.88% 17.71% -11.32%
Operating Cash Flow Q/Q Growth		 0.00% 7.48% 30.96% -17.41% 1.16% 2.92% 2.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -17.47% 1.77% 0.67% 4.65%
Invested Capital Q/Q Growth		 0.00% 0.00% -187.87% 1.01% 1.90% 2.17% 0.94%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -15,412.33% -7,189.84% -585.25% -305.30% -442.50% -264.07%
Operating Margin		 0.00% -15,937.44% -7,637.15% -609.20% -315.93% -454.31% -279.49%
EBIT Margin		 0.00% -15,720.70% -7,448.07% -595.78% -307.64% -435.89% -268.62%
Profit (Net Income) Margin		 0.00% -16,000.00% -7,681.58% -566.27% -288.17% -383.24% -240.33%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 104.49% 100.00% 100.00%
Interest Burden Percent		 101.07% 101.78% 103.14% 95.05% 89.65% 87.92% 89.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 3,473.37% -95.08% -83.37% -224.54% 255.39% 141.17% 96.45%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -48.64% -25.34% -24.78% -30.42% -34.57% -34.45%
Return on Assets (ROA)		 0.00% -49.51% -26.13% -23.55% -28.50% -30.40% -30.82%
Return on Common Equity (ROCE)		 207,684.85% -38.22% -83.37% -224.54% 255.39% 141.17% 96.45%
Return on Equity Simple (ROE_SIMPLE)		 58.09% -47.06% -104.59% 0.00% 127.51% 190.26% 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -48 -71 -82 -76 -72 -60
NOPAT Margin		 0.00% -11,156.21% -5,346.00% -426.44% -221.15% -318.02% -195.65%
Net Nonoperating Expense Percent (NNEP)		 -3,748.59% -25.02% -19.23% -10.75% -7.90% -6.17% -6.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 97.85% 157.88% 55.73%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 2,615.35% 1,647.31% 159.91% 94.78% 125.47% 89.13%
R&D to Revenue		 0.00% 13,422.09% 6,089.84% 549.29% 321.15% 418.23% 276.51%
Operating Expenses to Revenue		 0.00% 16,037.44% 7,737.15% 709.20% 415.93% 554.31% 379.49%
Earnings before Interest and Taxes (EBIT)		 -51 -68 -98 -115 -105 -99 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -50 -66 -95 -113 -104 -100 -82
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 4.97 8.76 2,381.22 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 4.97 8.76 2,381.22 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 1,688.24 643.13 13.87 7.97 11.61 9.88
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 1,301.92 526.15 0.00 1.12 0.83 4.70
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 -10.27 0.13 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -7.45 0.13 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.28 -1.15 -1.32 -5.16 7.52 3.89 2.62
Leverage Ratio		 -15.18 1.92 3.19 9.53 -8.96 -4.64 -3.13
Compound Leverage Factor		 -15.34 1.95 3.29 9.06 -8.03 -4.08 -2.80
Debt to Total Capital		 110.79% 11.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 30.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 80.35% 11.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 634.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -645.28% 88.15% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.30 -0.30 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.01 2.51 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.22 -0.30 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.42 -0.41 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.01 3.46 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.31 -0.41 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -10.12 3.02 0.82 -0.90 -2.19 -2.57 -4.47
Noncontrolling Interest Sharing Ratio		 -5,879.35% 59.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 1.33 10.12 9.44 6.37 4.11 3.73 2.73
Quick Ratio		 1.18 9.86 3.17 6.26 4.01 3.64 2.66
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -30 -33 206 -110 -94 -81
Operating Cash Flow to CapEx		 -4,806.54% -196.36% -1,516.75% 16,000.99% -9,649.18% -11,082.34% -172,198.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -24.92 -10.52 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -85.81 -26.05 -16.01 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -87.59 -39.32 -17.06 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.04 0.10 0.08 0.13
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.04 0.07 1.17 2.42 1.97 5.20
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -1.88 -20 -57 -346 -311 -289 -269
Invested Capital Turnover		 0.00 -0.04 -0.03 -0.10 -0.10 -0.08 -0.11
Increase / (Decrease) in Invested Capital		 0.00 -18 -37 -288 34 22 21
Enterprise Value (EV)		 206 560 694 -79 38 19 145
Market Capitalization		 120 726 848 267 272 262 305
Book Value per Share		 ($21.00) $4.08 $2.61 $0.00 ($1.83) ($0.82) ($1.92)
Tangible Book Value per Share		 ($21.00) $4.08 $2.61 $0.00 ($1.83) ($0.82) ($1.92)
Total Capital		 14 166 97 0.11 -77 -46 -109
Total Debt		 15 20 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 11 20 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.41 -166 -154 -346 -234 -244 -160
Capital Expenditures (CapEx)		 0.96 16 3.31 1.21 1.22 0.91 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.14 -14 257 -50 -52 -61 -57
Debt-free Net Working Capital (DFNWC)		 8.39 172 411 296 182 183 103
Net Working Capital (NWC)		 4.23 172 411 296 182 183 103
Net Nonoperating Expense (NNE)		 15 21 31 27 23 15 14
Net Nonoperating Obligations (NNO)		 -0.41 -166 -154 -346 -234 -244 -160
Total Depreciation and Amortization (D&A)		 0.69 1.33 3.41 2.03 0.80 -1.49 1.41
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -3,239.30% 19,452.69% -257.98% -153.16% -270.48% -183.27%
Debt-free Net Working Capital to Revenue		 0.00% 39,963.02% 31,150.11% 1,540.43% 532.12% 807.95% 334.84%
Net Working Capital to Revenue		 0.00% 39,963.02% 31,150.11% 1,540.43% 532.12% 807.95% 334.84%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($6.23) $0.00 ($2.62) ($2.34) ($1.58) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 36.82M 0.00 41.59M 41.97M 54.90M 62.98M
Adjusted Diluted Earnings per Share		 $0.00 ($6.23) $0.00 ($2.62) ($2.34) ($1.58) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 36.82M 0.00 41.59M 41.97M 54.90M 62.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($6.23) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.05M 0.00 41.80M 42.57M 55.61M 58.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -48 -71 -82 -76 -70 -56
Normalized NOPAT Margin		 0.00% -11,156.21% -5,346.00% -426.44% -221.15% -310.59% -182.25%
Pre Tax Income Margin		 0.00% -16,000.00% -7,681.58% -566.27% -275.80% -383.24% -240.33%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -93.68 -56.29 -31.30 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -66.22 -39.94 -22.46 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -95.47 -69.55 -32.35 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -68.01 -53.21 -23.52 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.68% 0.00%

Quarterly Metrics And Ratios for Foghorn Therapeutics

This table displays calculated financial ratios and metrics derived from Foghorn Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 41,862,174.00 42,217,126.00 42,565,904.00 42,585,616.00 55,328,655.00 - 55,612,239.00 55,741,373.00 56,529,969.00 56,551,289.00 58,700,246.00
DEI Adjusted Shares Outstanding		 41,862,174.00 42,217,126.00 42,565,904.00 42,585,616.00 55,328,655.00 - 55,612,239.00 55,741,373.00 56,529,969.00 56,551,289.00 58,700,246.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.32 -0.59 -0.59 -0.54 -0.35 - -0.34 -0.32 -0.28 -0.38 -0.34
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 163.46% 37.88% -4.88% 23.02% -55.33% -50.49% 17.86% 9.71% 4.42% 223.77% -45.11%
EBITDA Growth		 40.60% 21.19% 16.41% 17.41% -46.55% 4.16% 20.82% 22.99% 26.55% 2.25% -1.16%
EBIT Growth		 40.74% 20.73% 15.77% 17.52% -38.25% 8.80% 21.60% 21.68% 20.94% -3.44% -0.42%
NOPAT Growth		 39.56% 20.16% 15.38% 16.90% -39.64% 5.71% 18.73% 20.78% 22.43% 0.53% 5.85%
Net Income Growth		 44.33% 16.55% 17.95% 22.07% -33.30% 19.09% 24.71% 21.95% 17.12% -11.08% -5.53%
EPS Growth		 45.16% 17.39% 19.18% 35.71% 8.82% 59.65% 49.15% 37.78% 19.35% -52.17% 3.33%
Operating Cash Flow Growth		 -36.15% 4.78% 5.89% 20.63% 22.80% 10.97% 18.32% 17.77% 10.21% 9.17% -5.42%
Free Cash Flow Firm Growth		 -114.18% -119.65% -59.94% -47.21% 12.74% 25.80% 32.41% 28.62% 2.19% 3.69% 5.00%
Invested Capital Growth		 9.14% 9.96% 10.69% 10.24% 6.81% 7.06% 7.20% 7.65% 8.29% 7.13% 7.42%
Revenue Q/Q Growth		 212.16% -66.99% -12.46% 36.40% 13.36% -63.42% 108.40% 26.97% 7.89% 13.42% -64.67%
EBITDA Q/Q Growth		 48.22% -51.22% -11.26% 5.19% 8.13% 1.11% 8.07% 7.79% 12.37% -31.61% 4.86%
EBIT Q/Q Growth		 47.80% -51.47% -10.80% 5.85% 12.50% 0.08% 4.75% 5.95% 11.68% -30.73% 7.52%
NOPAT Q/Q Growth		 46.71% -49.04% -10.75% 5.54% 10.44% -0.64% 4.55% 7.93% 12.31% -29.06% 9.65%
Net Income Q/Q Growth		 51.35% -68.04% -3.78% 8.14% 16.78% -1.99% 3.43% 4.77% 11.64% -36.69% 8.26%
EPS Q/Q Growth		 51.43% -67.65% -3.51% 23.73% 31.11% 25.81% -30.43% 6.67% 10.71% -40.00% 17.14%
Operating Cash Flow Q/Q Growth		 15.43% -1.22% -6.55% 12.98% 17.75% -16.73% 2.25% 12.38% 10.19% -18.09% -13.45%
Free Cash Flow Firm Q/Q Growth		 -22.33% -19.09% -7.43% 5.95% 27.49% -1.27% 2.14% 0.67% 0.65% 0.28% 3.47%
Invested Capital Q/Q Growth		 4.91% 1.90% 2.28% 1.53% 1.27% 2.17% 2.43% 2.01% 1.95% 0.94% 2.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -92.41% -423.35% -538.10% -374.03% -303.14% -819.57% -361.51% -262.54% -213.23% -247.43% -666.27%
Operating Margin		 -97.73% -441.29% -558.30% -386.64% -305.48% -840.51% -384.96% -279.17% -226.92% -258.22% -660.33%
EBIT Margin		 -93.60% -429.54% -543.66% -375.28% -289.66% -791.28% -361.66% -267.90% -219.32% -252.80% -661.68%
Profit (Net Income) Margin		 -82.07% -417.85% -495.37% -333.61% -244.90% -682.88% -316.43% -237.34% -194.39% -234.28% -608.36%
Tax Burden Percent		 105.42% 108.98% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 83.17% 89.27% 91.12% 88.90% 84.55% 86.30% 87.49% 88.59% 88.64% 92.68% 91.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 624.26% 255.39% 152.29% 271.54% 212.95% 141.17% 101.09% 165.74% 122.30% 96.45% 109.12%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -8.16% -42.48% -58.70% -39.52% -23.77% -62.76% -33.10% -23.34% -20.95% -32.42% -77.67%
Return on Assets (ROA)		 -7.15% -41.32% -53.48% -35.14% -20.10% -54.17% -28.96% -20.68% -18.57% -30.04% -71.42%
Return on Common Equity (ROCE)		 624.26% 255.39% 152.29% 271.54% 212.95% 141.17% 101.09% 165.74% 122.30% 96.45% 109.12%
Return on Equity Simple (ROE_SIMPLE)		 179.84% 0.00% 95.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -18 -20 -19 -17 -17 -16 -15 -13 -17 -15
NOPAT Margin		 -68.41% -308.90% -390.81% -270.65% -213.84% -588.36% -269.47% -195.42% -158.85% -180.76% -462.23%
Net Nonoperating Expense Percent (NNEP)		 -0.75% -2.17% -2.02% -1.52% -0.92% -1.13% -1.31% -1.31% -1.29% -2.45% -2.35%
Return On Investment Capital (ROIC_SIMPLE)		 - 23.09% 20.24% 130.17% 59.03% 36.91% 26.02% 19.26% 14.44% 15.41% 19.76%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 47.53% 121.72% 152.67% 106.34% 89.28% 222.44% 121.62% 90.80% 81.59% 73.50% 201.44%
R&D to Revenue		 150.19% 419.57% 505.62% 345.48% 316.20% 718.07% 363.34% 288.37% 245.33% 238.41% 558.89%
Operating Expenses to Revenue		 197.73% 541.29% 658.30% 486.64% 405.48% 940.51% 484.96% 379.17% 326.92% 358.22% 760.33%
Earnings before Interest and Taxes (EBIT)		 -16 -25 -27 -26 -23 -23 -22 -20 -18 -23 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -24 -27 -26 -24 -23 -22 -20 -17 -23 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.43 7.97 8.43 6.96 20.19 11.61 8.64 10.84 11.27 9.88 9.94
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 1.12 2.33 0.00 9.71 0.83 0.00 2.57 3.87 4.70 3.39
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 19.16 7.52 4.28 8.94 6.15 3.89 2.68 5.33 3.81 2.62 2.94
Leverage Ratio		 -22.60 -8.96 -5.14 -10.49 -7.26 -4.64 -3.23 -6.10 -4.35 -3.13 -3.48
Compound Leverage Factor		 -18.80 -8.00 -4.69 -9.33 -6.14 -4.01 -2.82 -5.40 -3.86 -2.90 -3.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.91 -1.26 -1.71 -1.07 -0.85 -1.69 -2.21 -2.68 -3.20 -3.48 -3.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.10 4.11 4.06 5.69 4.77 3.73 3.16 2.62 2.16 2.73 2.92
Quick Ratio		 5.00 4.01 3.97 5.61 4.71 3.64 3.09 2.55 2.12 2.66 2.85
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -44 -52 -56 -53 -38 -39 -38 -38 -37 -37 -36
Operating Cash Flow to CapEx		 -33,182.93% -74,435.14% -29,054.46% -150,217.65% -6,797.73% -5,118.79% -85,600.00% -95,454.55% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.09 0.10 0.11 0.11 0.08 0.08 0.09 0.09 0.10 0.13 0.12
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 2.42 2.47 2.77 2.10 1.97 2.09 2.38 2.56 5.20 4.68
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -317 -311 -304 -299 -296 -289 -282 -277 -271 -269 -261
Invested Capital Turnover		 -0.10 -0.10 -0.11 -0.11 -0.08 -0.08 -0.08 -0.08 -0.09 -0.11 -0.10
Increase / (Decrease) in Invested Capital		 32 34 36 34 22 22 22 23 24 21 21
Enterprise Value (EV)		 -51 38 79 -40 248 19 -18 62 95 145 96
Market Capitalization		 209 272 286 245 515 262 203 262 276 305 281
Book Value per Share		 ($1.37) ($1.83) ($2.29) ($0.34) ($0.51) ($0.82) ($1.11) ($1.38) ($1.59) ($1.92) ($1.30)
Tangible Book Value per Share		 ($1.37) ($1.83) ($2.29) ($0.34) ($0.51) ($0.82) ($1.11) ($1.38) ($1.59) ($1.92) ($1.30)
Total Capital		 -57 -77 -97 -14 -28 -46 -62 -77 -90 -109 -76
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -260 -234 -207 -285 -267 -244 -221 -200 -182 -160 -185
Capital Expenditures (CapEx)		 0.08 0.04 0.10 0.02 0.31 0.48 0.03 0.02 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -46 -52 -47 -46 -53 -61 -66 -74 -82 -57 -61
Debt-free Net Working Capital (DFNWC)		 213 182 159 239 214 183 154 126 99 103 124
Net Working Capital (NWC)		 213 182 159 239 214 183 154 126 99 103 124
Net Nonoperating Expense (NNE)		 2.39 6.29 5.28 4.34 2.43 2.70 2.79 3.17 2.90 4.95 4.77
Net Nonoperating Obligations (NNO)		 -260 -234 -207 -285 -267 -244 -221 -200 -182 -160 -185
Total Depreciation and Amortization (D&A)		 0.21 0.36 0.28 0.09 -1.05 -0.81 0.01 0.41 0.50 0.50 -0.15
Debt-free, Cash-free Net Working Capital to Revenue		 -142.64% -153.16% -139.27% -131.95% -207.67% -270.48% -282.85% -305.54% -336.48% -183.27% -216.91%
Debt-free Net Working Capital to Revenue		 655.30% 532.12% 470.42% 678.56% 840.33% 807.95% 655.66% 521.47% 403.90% 334.84% 438.14%
Net Working Capital to Revenue		 655.30% 532.12% 470.42% 678.56% 840.33% 807.95% 655.66% 521.47% 403.90% 334.84% 438.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.34) ($0.57) ($0.59) ($0.45) ($0.31) ($0.23) ($0.30) ($0.28) ($0.25) ($0.35) ($0.29)
Adjusted Weighted Average Basic Shares Outstanding		 42.03M 41.97M 42.43M 51.58M 62.60M 54.90M 62.85M 62.98M 63.03M 62.98M 69.54M
Adjusted Diluted Earnings per Share		 ($0.34) ($0.57) ($0.59) ($0.45) ($0.31) ($0.23) ($0.30) ($0.28) ($0.25) ($0.35) ($0.29)
Adjusted Weighted Average Diluted Shares Outstanding		 42.03M 41.97M 42.43M 51.58M 62.60M 54.90M 62.85M 62.98M 63.03M 62.98M 69.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.22M 42.57M 42.59M 55.33M 55.59M 55.61M 55.74M 56.53M 56.55M 58.70M 58.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -18 -20 -17 -17 -17 -16 -15 -13 -17 -15
Normalized NOPAT Margin		 -68.41% -308.90% -390.81% -246.28% -213.84% -588.36% -269.47% -195.42% -158.85% -180.76% -462.23%
Pre Tax Income Margin		 -77.85% -383.43% -495.37% -333.61% -244.90% -682.88% -316.43% -237.34% -194.39% -234.28% -608.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.23% -0.64% -0.68% 0.00% -0.52% 0.00% 0.00% -0.42%

Financials Breakdown Chart

Foghorn Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Foghorn Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Foghorn Therapeutics' net income appears to be on an upward trend, with a most recent value of -$74.28 million in 2025, rising from -$51.13 million in 2019. The previous period was -$86.62 million in 2024. See where experts think Foghorn Therapeutics is headed by visiting Foghorn Therapeutics' forecast page.

Foghorn Therapeutics' total operating income in 2025 was -$86.39 million, based on the following breakdown:
  • Total Gross Profit: $30.91 million
  • Total Operating Expenses: $117.30 million

Over the last 6 years, Foghorn Therapeutics' total revenue changed from $0.00 in 2019 to $30.91 million in 2025, a change of 3,090,900,000.0%.

Foghorn Therapeutics' total liabilities were at $306.60 million at the end of 2025, a 7.0% decrease from 2024, and a 1,187.5% increase since 2019.

In the past 6 years, Foghorn Therapeutics' cash and equivalents has ranged from $14.98 million in 2019 to $101.14 million in 2021, and is currently $80.88 million as of their latest financial filing in 2025.

Over the last 6 years, Foghorn Therapeutics' book value per share changed from -21.00 in 2019 to -1.92 in 2025, a change of -90.9%.


Related Companies

Financial statements for NASDAQ:FHTX last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Gold to $4,900—Here’s the Real Play
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
He turned $12,415 into millions. Now he wants to help you.
Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...
Tim Sykes | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel